A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events
- PMID: 40394856
- PMCID: PMC12092964
- DOI: 10.1002/sim.70104
A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events
Abstract
In randomized clinical trials, stopping study medication, use of rescue treatment, and other intercurrent events can complicate interpretation of results. The ICH E9(R1) Addendum on estimands stimulated important cross-disciplinary discussions on trial objectives. Unfortunately, with influence of the Addendum, many trials have proposed analyzing primary endpoints using "while on treatment", "hypothetical", or "principal stratum" strategies that handle intercurrent events in ways that use post-randomization outcomes to exclude information from randomized participants and don't preserve integrity of randomization, or that don't reliably capture the intervention's meaningful net effects. These approaches have inherent limitations in ability to draw scientifically rigorous inference on clinically relevant causal effects important for decisions about adopting interventions. We describe advantages of trials with standard-of-care control arms targeting estimands using "treatment policy" approaches for intercurrent events, while potentially incorporating other meaningful intercurrent events, such as death, into the primary endpoint applying a composite strategy. Well-designed and -conducted trials targeting such estimands achieve scientifically rigorous causal inference through analyzes that protect the integrity of randomization. Such estimands also provide meaningful information relevant to real-world settings because they (1) are unconditional in nature i.e., they don't condition on post-treatment circumstances that might not be many participants' experiences; and (2) properly evaluate the experimental intervention within a regimen that includes possible ancillary care that would be clinically appropriate in real-world settings. We hope to add clarity about appropriate strategies for intercurrent events and how to improve design, conduct, and analysis of clinical trials to address questions of greatest clinical importance reliably.
Keywords: causal inference; estimands; intercurrent events; randomization.
© 2025 The Author(s). Statistics in Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.Ther Innov Regul Sci. 2020 Mar;54(2):324-341. doi: 10.1007/s43441-019-00061-x. Epub 2020 Jan 4. Ther Innov Regul Sci. 2020. PMID: 32072573
-
Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1).Stat Med. 2025 May;44(10-12):e70091. doi: 10.1002/sim.70091. Stat Med. 2025. PMID: 40386918
-
Estimating hypothetical estimands with causal inference and missing data estimators in a diabetes trial case study.Biometrics. 2025 Jan 7;81(1):ujae167. doi: 10.1093/biomtc/ujae167. Biometrics. 2025. PMID: 39873640
-
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.Value Health. 2023 Feb;26(2):234-242. doi: 10.1016/j.jval.2022.08.008. Epub 2022 Sep 21. Value Health. 2023. PMID: 36150999 Review.
-
A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?Trials. 2020 Jul 23;21(1):671. doi: 10.1186/s13063-020-04546-1. Trials. 2020. PMID: 32703247 Free PMC article. Review.
References
-
- European Medicines Agency , ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials (ICH, 2020).
-
- National Research Council (US) Panel on Handling Missing Data in Clinical Trials , The Prevention and Treatment of Missing Data in Clinical Trials (National Academies Press, 2010), 162. - PubMed
-
- Friedman L. M., Furberg C. D., DeMets D. L., Reboussin D. M., and Granger C. B., Fundamentals of Clinical Trials, 5th ed. (Springer, 2015), 550.
-
- Rothwell R., Nikolov N. P., Maynard J. W., and Levin G., “Noninferiority Trials to Evaluate Drug Effects in Rheumatoid Arthritis,” Arthritis & Rhematology 72, no. 8 (2020): 1258–1265. - PubMed
-
- DeMets D. L., Psaty B. M., and Fleming T. R., “When Can Intermediate Outcomes Be Used as Surrogate Outcomes?,” Jama 323, no. 12 (2020): 1184–1185. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources